Exosomes for hair loss
Exosome therapy for androgenetic alopecia in the UK, set against platelet rich plasma and the licensed minoxidil and finasteride class, with the regulatory position stated plainly.
Published by Northbank Media. Last reviewed 2026-07-31. Information only. This site is not a clinic and gives no medical advice.
Exosome therapy is offered for androgenetic alopecia on the argument that vesicle signalling can extend the growth phase of a miniaturising follicle. The rationale is coherent. The human evidence supporting a specific outcome is not yet there.
For pattern hair loss there are options with regulatory approval and decades of clinical data behind them. An unlicensed treatment is a reasonable thing to consider after you understand those, and a poor thing to reach for instead of them.
Androgenetic alopecia is the most common cause of hair loss in both men and women. It is progressive, it is driven substantially by genetics and androgen sensitivity, and the follicles involved do not disappear all at once. They miniaturise: each cycle produces a slightly finer, shorter, less pigmented hair until the shaft is barely visible. Every medical hair treatment on the market is trying to interrupt that process somewhere.
Why exosomes were proposed for hair at all
The follicle is not a static structure. It cycles through growth, regression and rest, and the switch between those phases is governed by signalling between the dermal papilla at the base of the follicle and the cells around it. The bulge region holds the stem cell population that regenerates the follicle at the start of each new cycle. Anything that could lengthen the growth phase, delay regression or improve the blood supply feeding the papilla is a plausible target.
Extracellular vesicles participate in exactly this kind of cell to cell signalling. Laboratory work has shown vesicles from various source cells influencing dermal papilla cell behaviour in culture, and animal work has shown changes in hair cycling in treated mice. That is a genuine scientific basis for asking the question. It is not an answer to it.
The gap between mouse and man is wide in hair biology specifically. Rodent hair cycles are synchronised across the body in waves, human follicles cycle independently of one another, and the mechanisms driving androgenetic alopecia in humans are not reproduced in a mouse. A treatment that changes hair cycling in a mouse has cleared a low bar, not a high one.
What a scalp session involves
The usual protocol is topical. Anaesthetic cream is applied to the scalp and left to work. The scalp is cleansed. A microneedling device is passed over the thinning areas at a depth typically shallower than facial settings. The vesicle preparation is applied to the surface and worked in. You are asked not to wash the scalp for a period, usually up to twenty four hours, and to avoid heat and sweating for a day or two.
Three sessions two to four weeks apart is the common starting course. Maintenance intervals vary between clinics from three months to a year, which is a reasonable signal that the interval is commercially rather than biologically determined. There is no consensus protocol because there is no body of trial evidence from which one could be derived.
Some clinics offer injection into the scalp instead. That is not a licensed route for any exosome product in the UK and it should be discussed on that basis. A practitioner offering it should be able to state what the product is, what it is classed as, and what their justification is. If they cannot, that is your answer.
Set against the treatments that have a licence
This is the comparison that matters most, and it is the one clinic marketing tends to skip. For androgenetic alopecia, unlike for most aesthetic concerns, there are treatments that have been through regulatory assessment and carry decades of clinical use.
| Option | UK regulatory status | Evidence base | Commitment | Main drawbacks |
|---|---|---|---|---|
| Topical minoxidil | Licensed in the UK for androgenetic alopecia, available without prescription | Large trial base over decades | Daily application, indefinitely | Scalp irritation, unwanted hair growth, shedding on starting |
| Oral finasteride | Prescription only medicine, licensed for men, not licensed for women | Large trial base over decades | Daily tablet, indefinitely | Sexual side effects and mood effects reported, requires a proper prescribing discussion |
| Platelet rich plasma | No marketing authorisation for this indication | Moderate, small studies, mixed protocols | Course then maintenance | Bruising, tenderness, cost, unpredictable response |
| Exosome preparations | No marketing authorisation for this indication | Early, mostly laboratory and animal, small human studies | Course then maintenance at undefined intervals | Needling risks, unquantified product risks, no standardisation |
| Hair transplantation | Surgical procedure, regulated through the practitioner and the setting | Established as a surgical technique | One or more procedures, permanent redistribution | Surgical risks, does not stop ongoing loss elsewhere |
Reading that table fairly means noticing the asymmetry. The licensed options are not miracle treatments. Topical minoxidil helps a proportion of users, needs to be continued indefinitely, and often produces stabilisation rather than dramatic regrowth. Oral finasteride is a prescription only medicine for men in the UK with a side effect profile that must be discussed properly before it is started, and it is not licensed for use in women. Neither is a comfortable universal answer.
But they have been assessed. Their benefits and their harms have been characterised in trials with thousands of participants and years of follow up. That is a category of knowledge that does not exist for exosome preparations and will not exist for several years at the earliest. Choosing the unassessed option first is a choice; it should not be made by default because a clinic offered it and no one mentioned the alternatives.
Set against platelet rich plasma
Platelet rich plasma is the closest comparator in practice, because it occupies the same commercial position: a regenerative treatment sold as a course, delivered into the scalp, without a marketing authorisation for the indication. Both are offered on a signalling rationale, both are usually sold in packages of three or more, and both have a literature limited by small samples and heterogeneous protocols.
The practical differences are worth understanding.
Platelet rich plasma
- Derived from your own blood, drawn and processed at the appointment. What is administered came from you.
- Requires a blood draw and a centrifuge step, which adds time and a needle.
- Content varies with your own platelet count, hydration and the preparation system, which is a source of inconsistency between sessions and between clinics.
- The published literature is larger and includes randomised work, though still with small numbers and mixed protocols.
Exosome preparations
- Supplied by a third party in a vial. You cannot verify the content and neither, in most cases, can the clinic.
- No blood draw. Session time is shorter.
- Content should in principle be consistent batch to batch, but consistency depends on the manufacturer's quality system, which is not visible to you.
- The human literature is smaller, newer and more product specific, so results do not transfer between preparations.
What a realistic result looks like
If you proceed, the outcome to expect is not regrowth of a lost hairline. It is, at best, a slowing of miniaturisation and a modest improvement in the calibre and density of hairs that are still cycling. That change takes months to appear and months more to become measurable. It requires standardised photography at fixed intervals to detect at all, because ordinary week to week variation in styling and lighting is larger than the effect.
There is a specific trap here. Any needling procedure on the scalp can trigger a temporary increase in shedding in the weeks afterwards as follicles are pushed into a new cycle. Some clinics present this as a positive sign. It is a known consequence of disturbing the scalp and it says nothing either way about the final result. If you are told that shedding proves the treatment is working, ask what evidence supports that statement.
Before you book anything
Get a diagnosis first. Androgenetic alopecia is common but it is not the only cause of hair loss, and several of the alternatives need entirely different management. Telogen effluvium after illness or stress usually resolves on its own. Alopecia areata is autoimmune and treated differently. Scarring alopecias destroy follicles permanently and need specialist dermatology input urgently, because time matters. Iron deficiency and thyroid disease can both present as diffuse thinning. The British Association of Dermatologists publishes patient information covering these.
A clinic that sells a course of scalp treatment without establishing what is causing your hair loss is selling you a treatment, not treating your condition. Ask what the diagnosis is and what it is based on. Then take the twelve consultation questions with you and write the answers down.
Common questions
Will exosomes regrow hair I have already lost
No treatment reliably regrows hair from a follicle that has been lost rather than miniaturised. What any medical hair treatment realistically targets is follicles that are still present but producing finer, shorter hairs. If an area has been completely smooth for years, the follicles are usually gone and the discussion is about transplantation rather than about topical or injected treatments.
How does it compare with platelet rich plasma
Both are offered on a regenerative rationale, both involve repeated sessions, and both have a published literature that is larger for platelet rich plasma but still limited by small studies and inconsistent protocols. Platelet rich plasma has the practical advantage of being derived from your own blood at the point of treatment, which removes the question of what is in the vial. It has the disadvantage of varying with your own blood and with the preparation system used.
How long before I could tell whether it has done anything
At least three to six months, because of how slowly the hair cycle turns. A course delivered over six weeks cannot be assessed at the end of it. Anyone assessing your result at week eight is measuring the shedding pattern, not the outcome. Standardised photographs taken at fixed intervals under the same lighting are the only useful way to judge.
Is exosome therapy for hair loss licensed in the UK
No exosome product holds a UK marketing authorisation for any hair indication. The route offered is topical application to a scalp prepared by microneedling. Injection into the scalp is not a licensed route for any exosome preparation. Read risks and regulation before consenting to anything.
Can I use it alongside minoxidil or finasteride
Many clinics suggest it as an addition rather than a replacement, and that is the more defensible framing. It is also the framing that makes any individual result impossible to attribute. If you start two things at once you will not know which one worked. Discuss sequencing with the clinician prescribing your licensed treatment rather than with the clinic selling the additional one.
This page contains no commercial links of any kind. No clinic, practitioner, product or supplier is named, recommended or linked to, and nobody has paid for, influenced or previewed anything on it. External links go only to UK regulators and professional bodies and carry a nofollow attribute. Published by Northbank Media under our editorial policy.
If you want to speak to someone
We are not a clinic and we give no medical advice. If you would like to, we can pass your details to a registered UK practitioner who will contact you directly. Nothing is booked on your behalf and there is no obligation. Read the regulation page first.
Make an enquiry